All coronavirus articles
-
BusinessNew Covid-19 antiviral cuts symptoms by 1.5 days
Simnotrelvir already has emergency approval in China
-
OpinionSetting drug development speed records
The pandemic treatment sprint was spectacular, but hard to match under less unusual circumstances
-
BusinessPharmaceuticals roundup 2022
Following the huge success of vaccines and treatments for covid-19, companies are upping their investment in R&D and dealmaking
-
BusinessProtective treatment for Covid-19 makes minimal impact
Limited uptake of antibody combination for vulnerable patients, while demand for antivirals seems to be slowing
-
BusinessWhat is the future of Covid-19 pharmaceuticals?
Firms anticipate long-term markets for prevention and treatment
-
NewsUK’s non-profit vaccine manufacturing centre sold off before opening
Pharmaceutical firm Catalent buys government-backed facility near Oxford
-
BusinessModerna sued over Covid-19 vaccine-related patents
Arbutus and Genevant say lipid nanoparticles that protect mRNA infringe six key patents
-
OpinionLiving through Covid-19
Many researchers are now feeling the effects of additional emotional burdens
-
NewsExplainer: How do the Covid vaccines measure up against each other and omicron?
Looking at how the evidence stacks up for vaccines against variants and how their performance holds up over time
-
OpinionThe shadow of drug resistance
Why do some medicines stop working, and can we avoid it for Covid-19 antivirals?
-
CareersThe conference conundrum
Following the Covid-19 pandemic, is it time to rethink events for good?
-
BusinessPharmaceuticals roundup 2021
It’s been another dramatic, pandemic-dominated year for the pharmaceutical industry
-
BusinessCovid-19 antivirals surge forward
Promising results from Pfizer trial, while UK approves Merck & Co’s molnupiravir
-
FeaturemRNA vaccines for Covid and beyond
Already hailed as a miracle, the new vaccine technology could protect us from other diseases, Clare Sansom finds
-
BusinessNew antiviral impresses against Covid-19
Merck & Co and Ridgeback’s molnupiravir reduces risk of hospitalisation and death, and may work against other coronaviruses
-
OpinionWhere are the Covid-19 drugs?
Small molecules appear to be lagging behind development of vaccine and antibody treatments
-
OpinionLeading a lab through pandemic-induced uncertainty
Emphathy is vital to support mentees effectively
-
-
OpinionLights, smartphones, action!
How an intrepid group of technicians adventured into the world of filmmaking
-
BusinessThe future of ‘next generation’ DNA sequencing
As it gets cheaper and easier to read genetic code, its applications are expanding rapidly